Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
SOPHIRIS BIO INC. (SPHS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/03/2020 |
8-K
| Other Events |
| 03/31/2020 |
8-K
| Quarterly results |
| 03/11/2020 |
8-K
| Quarterly results |
| 12/23/2019 |
8-K
| Quarterly results |
| 12/13/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/13/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/09/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 11/07/2019 |
8-K
| Quarterly results |
| 10/22/2019 |
8-K
| Quarterly results |
| 10/08/2019 |
8-K/A
| Quarterly results |
| 09/12/2019 |
8-K
| Quarterly results |
| 08/27/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 08/09/2019 |
8-K
| Quarterly results|
Docs:
|
"Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, August 9, 2019 – Sophiris Bio Inc. , a biopharmaceutical company studying topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the second quarter 2019 and recent corporate highlights. “During the second quarter of 2019, we received positive feedback from the EMA regarding the design of our Phase 3 clinical trial for localized prostate cancer which was a significant step forward in our development of topsalysin,” said Randall E. Woods, president and CEO of Sophiris. “We are now focused on our plan to fund this study and the Company going ..." |
|
| 06/28/2019 |
8-K
| Quarterly results |
| 06/07/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 05/09/2019 |
8-K
| Quarterly results|
Docs:
|
"Sophiris Bio Reports First Quarter 2019 Financial Results SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 – Sophiris Bio Inc. , a biopharmaceutical company developing topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the first quarter of 2019. “We continue to have dialog with the European Medicines Agency regarding the design for a potential Phase 3 clinical trial, which we developed with input from our scientific advisory board for the treatment of localized prostate cancer,” said Randall E. Woods, president and CEO of Sophiris. “We anticipate obtaining formal scientific advice from the EMA before the end of the second quarter and look forward to taking the ..." |
|
| 03/13/2019 |
8-K
| Quarterly results|
Docs:
|
"Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 – Sophiris Bio Inc. , a biopharmaceutical company developing topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. “During the past year, Sophiris has made important progress in determining the ideal method for topsalysin administration as a focal treatment for localized prostate cancer,” said Randall E. Woods, president and CEO of Sophiris. “The Phase 2b study provided a compelling look at this potential, showing that a single administratio..." |
|
| 01/03/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/17/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/07/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/13/2018 |
8-K
| Quarterly results |
| 08/30/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/28/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/25/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/14/2018 |
8-K
| Quarterly results |
| 03/21/2018 |
8-K
| Quarterly results |
| 12/08/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/09/2017 |
8-K
| Quarterly results |
| 09/13/2017 |
8-K
| Quarterly results |
| 08/10/2017 |
8-K
| Quarterly results |
| 06/02/2017 |
8-K
| Form 8-K - Current report |
| 05/15/2017 |
8-K
| Quarterly results |
| 03/27/2017 |
8-K
| Form 8-K - Current report |
| 03/17/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|